APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vasculitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vasculitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174045320319 December 2025187 pages

Choose your research edition.

Industry ResearchVasculitis Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Vasculitis Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Vasculitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vasculitis Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Vasculitis Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Vasculitis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vasculitis Drug include Shanghaihuangxiang Lantian Pharmaceutical, Merck, Huzhou Konch Pharmaceutical, Hubei Biocause Pharmaceutical, Hainan Pharmaceutical Factory, Bayer, Sino-US Zibo Xinhua-Perrigo Pharmaceutical, Farmalider and CSPC Ouyi Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vasculitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vasculitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vasculitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vasculitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Vasculitis Drug Segment by Company

Shanghaihuangxiang Lantian Pharmaceutical

Merck

Huzhou Konch Pharmaceutical

Hubei Biocause Pharmaceutical

Hainan Pharmaceutical Factory

Bayer

Sino-US Zibo Xinhua-Perrigo Pharmaceutical

Farmalider

CSPC Ouyi Pharmaceutical

Vasculitis Drug Segment by Type

CCX-168

Blisibimod

Gevokizumab

Rituximab Biosimilar

Others

Vasculitis Drug Segment by Application

Thrombotic Vasculitis

Granulomatous Vasculitis

Lymphocytic Vasculitis

Polyarteritis Nodosa

Others

Vasculitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasculitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vasculitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasculitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vasculitis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vasculitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vasculitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vasculitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vasculitis Drug Industry Trends Table 2. Vasculitis Drug Industry Drivers Table 3. Vasculitis Drug Industry Opportunities and Challenges Table 4. Vasculitis Drug Industry Restraints Table 5. Global Vasculitis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vasculitis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vasculitis Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vasculitis Drug Sales Market Share by Manufacturers Table 9. Global Vasculitis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vasculitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vasculitis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vasculitis Drug Manufacturers, Product Type & Application Table 13. Global Vasculitis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vasculitis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CCX-168 Table 17. Major Manufacturers of Blisibimod Table 18. Major Manufacturers of Gevokizumab Table 19. Major Manufacturers of Rituximab Biosimilar Table 20. Major Manufacturers of Others Table 21. Global Vasculitis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Vasculitis Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Vasculitis Drug Sales Market Share by Type (2021-2026) Table 25. Global Vasculitis Drug Sales Market Share by Type (2027-2032) Table 26. Global Vasculitis Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Vasculitis Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Vasculitis Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Vasculitis Drug Revenue Market Share by Type (2021-2026) Table 30. Global Vasculitis Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Thrombotic Vasculitis Table 32. Major Manufacturers of Granulomatous Vasculitis Table 33. Major Manufacturers of Lymphocytic Vasculitis Table 34. Major Manufacturers of Polyarteritis Nodosa Table 35. Major Manufacturers of Others Table 36. Global Vasculitis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 38. Global Vasculitis Drug Sales by Application (2027-2032) & (K Units) Table 39. Global Vasculitis Drug Sales Market Share by Application (2021-2026) Table 40. Global Vasculitis Drug Sales Market Share by Application (2027-2032) Table 41. Global Vasculitis Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Vasculitis Drug Revenue by Application (2021-2026) & (K Units) Table 43. Global Vasculitis Drug Revenue by Application (2027-2032) & (K Units) Table 44. Global Vasculitis Drug Revenue Market Share by Application (2021-2026) Table 45. Global Vasculitis Drug Revenue Market Share by Application (2027-2032) Table 46. Global Vasculitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Vasculitis Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Vasculitis Drug Sales Market Share by Region (2021-2026) Table 49. Global Vasculitis Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Vasculitis Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 53. North America Vasculitis Drug Sales by Country (2027-2032) & (K Units) Table 54. Europe Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 56. Europe Vasculitis Drug Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Vasculitis Drug Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Vasculitis Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Vasculitis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Vasculitis Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Vasculitis Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Vasculitis Drug Revenue Market Share by Region (2021-2026) Table 67. Global Vasculitis Drug Revenue Market Share by Region (2027-2032) Table 68. Shanghaihuangxiang Lantian Pharmaceutical Company Information Table 69. Shanghaihuangxiang Lantian Pharmaceutical Business Overview Table 70. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio Table 72. Shanghaihuangxiang Lantian Pharmaceutical Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Merck Vasculitis Drug Product Portfolio Table 77. Merck Recent Development Table 78. Huzhou Konch Pharmaceutical Company Information Table 79. Huzhou Konch Pharmaceutical Business Overview Table 80. Huzhou Konch Pharmaceutical Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio Table 82. Huzhou Konch Pharmaceutical Recent Development Table 83. Hubei Biocause Pharmaceutical Company Information Table 84. Hubei Biocause Pharmaceutical Business Overview Table 85. Hubei Biocause Pharmaceutical Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio Table 87. Hubei Biocause Pharmaceutical Recent Development Table 88. Hainan Pharmaceutical Factory Company Information Table 89. Hainan Pharmaceutical Factory Business Overview Table 90. Hainan Pharmaceutical Factory Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio Table 92. Hainan Pharmaceutical Factory Recent Development Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Bayer Vasculitis Drug Product Portfolio Table 97. Bayer Recent Development Table 98. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information Table 99. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Business Overview Table 100. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio Table 102. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Development Table 103. Farmalider Company Information Table 104. Farmalider Business Overview Table 105. Farmalider Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Farmalider Vasculitis Drug Product Portfolio Table 107. Farmalider Recent Development Table 108. CSPC Ouyi Pharmaceutical Company Information Table 109. CSPC Ouyi Pharmaceutical Business Overview Table 110. CSPC Ouyi Pharmaceutical Vasculitis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio Table 112. CSPC Ouyi Pharmaceutical Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Vasculitis Drug Distributors List Table 116. Vasculitis Drug Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Vasculitis Drug Product Image Figure 2. Global Vasculitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vasculitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Vasculitis Drug Sales (2021-2032) & (K Units) Figure 5. Global Vasculitis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vasculitis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CCX-168 Image Figure 9. Blisibimod Image Figure 10. Gevokizumab Image Figure 11. Rituximab Biosimilar Image Figure 12. Others Image Figure 13. Global Vasculitis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Vasculitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Vasculitis Drug Sales Market Share by Type (2021-2032) Figure 16. Global Vasculitis Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Vasculitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Vasculitis Drug Revenue Market Share by Type (2021-2032) Figure 19. Thrombotic Vasculitis Image Figure 20. Granulomatous Vasculitis Image Figure 21. Lymphocytic Vasculitis Image Figure 22. Polyarteritis Nodosa Image Figure 23. Others Image Figure 24. Global Vasculitis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Vasculitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Vasculitis Drug Sales Market Share by Application (2021-2032) Figure 27. Global Vasculitis Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Vasculitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Vasculitis Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Vasculitis Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Vasculitis Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Vasculitis Drug Sales Market Share by Country (2021-2032) Figure 44. China Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Vasculitis Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Vasculitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Vasculitis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Vasculitis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Vasculitis Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Vasculitis Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Vasculitis Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Vasculitis Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Vasculitis Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Vasculitis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • CCX-168
  • Blisibimod
  • Gevokizumab
  • Rituximab Biosimilar
  • Others
Applications
  • Thrombotic Vasculitis
  • Granulomatous Vasculitis
  • Lymphocytic Vasculitis
  • Polyarteritis Nodosa
  • Others
Companies covered
  • Shanghaihuangxiang Lantian Pharmaceutical
  • Merck
  • Huzhou Konch Pharmaceutical
  • Hubei Biocause Pharmaceutical
  • Hainan Pharmaceutical Factory
  • Bayer
  • Sino-US Zibo Xinhua-Perrigo Pharmaceutical
  • Farmalider
  • CSPC Ouyi Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vasculitis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vasculitis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vasculitis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vasculitis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vasculitis Drug Market Dynamics
  1. 2.1 Vasculitis Drug Industry Trends
  2. 2.2 Vasculitis Drug Industry Drivers
  3. 2.3 Vasculitis Drug Industry Opportunities and Challenges
  4. 2.4 Vasculitis Drug Industry Restraints
3 Vasculitis Drug Market by Manufacturers
  1. 3.1 Global Vasculitis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vasculitis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vasculitis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vasculitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vasculitis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vasculitis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Vasculitis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vasculitis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vasculitis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vasculitis Drug Tier 1, Tier 2, and Tier 3
4 Vasculitis Drug Market by Type
  1. 4.1 Vasculitis Drug Type Introduction
  2. 4.1.1 CCX-168
  3. 4.1.2 Blisibimod
  4. 4.1.3 Gevokizumab
  5. 4.1.4 Rituximab Biosimilar
  6. 4.1.5 Others
  7. 4.2 Global Vasculitis Drug Sales by Type
  8. 4.2.1 Global Vasculitis Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Vasculitis Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Vasculitis Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Vasculitis Drug Revenue by Type
  12. 4.3.1 Global Vasculitis Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Vasculitis Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Vasculitis Drug Revenue Market Share by Type (2021-2032)
5 Vasculitis Drug Market by Application
  1. 5.1 Vasculitis Drug Application Introduction
  2. 5.1.1 Thrombotic Vasculitis
  3. 5.1.2 Granulomatous Vasculitis
  4. 5.1.3 Lymphocytic Vasculitis
  5. 5.1.4 Polyarteritis Nodosa
  6. 5.1.5 Others
  7. 5.2 Global Vasculitis Drug Sales by Application
  8. 5.2.1 Global Vasculitis Drug Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Vasculitis Drug Sales by Application (2021-2032)
  10. 5.2.3 Global Vasculitis Drug Sales Market Share by Application (2021-2032)
  11. 5.3 Global Vasculitis Drug Revenue by Application
  12. 5.3.1 Global Vasculitis Drug Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Vasculitis Drug Revenue by Application (2021-2032)
  14. 5.3.3 Global Vasculitis Drug Revenue Market Share by Application (2021-2032)
6 Global Vasculitis Drug Sales by Region
  1. 6.1 Global Vasculitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vasculitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Vasculitis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Vasculitis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vasculitis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vasculitis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vasculitis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vasculitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vasculitis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vasculitis Drug Revenue by Region
  1. 7.1 Global Vasculitis Drug Revenue by Region
  2. 7.1.1 Global Vasculitis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vasculitis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Vasculitis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Vasculitis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vasculitis Drug Revenue (2021-2032)
  8. 7.2.2 North America Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vasculitis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vasculitis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vasculitis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vasculitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghaihuangxiang Lantian Pharmaceutical
  2. 8.1.1 Shanghaihuangxiang Lantian Pharmaceutical Company Information
  3. 8.1.2 Shanghaihuangxiang Lantian Pharmaceutical Business Overview
  4. 8.1.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio
  6. 8.1.5 Shanghaihuangxiang Lantian Pharmaceutical Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Vasculitis Drug Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Huzhou Konch Pharmaceutical
  14. 8.3.1 Huzhou Konch Pharmaceutical Company Information
  15. 8.3.2 Huzhou Konch Pharmaceutical Business Overview
  16. 8.3.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio
  18. 8.3.5 Huzhou Konch Pharmaceutical Recent Developments
  19. 8.4 Hubei Biocause Pharmaceutical
  20. 8.4.1 Hubei Biocause Pharmaceutical Company Information
  21. 8.4.2 Hubei Biocause Pharmaceutical Business Overview
  22. 8.4.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio
  24. 8.4.5 Hubei Biocause Pharmaceutical Recent Developments
  25. 8.5 Hainan Pharmaceutical Factory
  26. 8.5.1 Hainan Pharmaceutical Factory Company Information
  27. 8.5.2 Hainan Pharmaceutical Factory Business Overview
  28. 8.5.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio
  30. 8.5.5 Hainan Pharmaceutical Factory Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Vasculitis Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Sino-US Zibo Xinhua-Perrigo Pharmaceutical
  38. 8.7.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information
  39. 8.7.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Business Overview
  40. 8.7.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio
  42. 8.7.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments
  43. 8.8 Farmalider
  44. 8.8.1 Farmalider Company Information
  45. 8.8.2 Farmalider Business Overview
  46. 8.8.3 Farmalider Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Farmalider Vasculitis Drug Product Portfolio
  48. 8.8.5 Farmalider Recent Developments
  49. 8.9 CSPC Ouyi Pharmaceutical
  50. 8.9.1 CSPC Ouyi Pharmaceutical Company Information
  51. 8.9.2 CSPC Ouyi Pharmaceutical Business Overview
  52. 8.9.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio
  54. 8.9.5 CSPC Ouyi Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vasculitis Drug Value Chain Analysis
  2. 9.1.1 Vasculitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vasculitis Drug Production Mode & Process
  6. 9.2 Vasculitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vasculitis Drug Distributors
  9. 9.2.3 Vasculitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst